Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.48 per share and revenue of $155.7920 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $31.49 on Wednesday. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a PEG ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56. The firm has a fifty day simple moving average of $31.40 and a 200 day simple moving average of $27.45.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CPRX shares. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. HC Wainwright downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Finally, Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Institutional Trading of Catalyst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CPRX. Parkside Financial Bank & Trust increased its stake in shares of Catalyst Pharmaceuticals by 17.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares during the period. E Fund Management Co. Ltd. lifted its stake in Catalyst Pharmaceuticals by 8.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 871 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Catalyst Pharmaceuticals by 6.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 16,080 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 927 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in Catalyst Pharmaceuticals by 1.0% during the second quarter. California State Teachers Retirement System now owns 99,257 shares of the biopharmaceutical company’s stock worth $2,154,000 after purchasing an additional 992 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).